Ardelyx Shares Fall After IBS Drug Sales Hit Snags

Dow Jones08-07

Ardelyx shares were lower in pre-market trading after the company cut its outlook for its irritable bowel syndrome treatment.

The stock fell 20% to $3.90 before the opening bell Friday. Through the prior close, shares were already down 21% this year.

The commercial-stage biopharmaceutical company said Thursday evening that it now expects full-year revenue for its IBS treatment Ibsrela to be $350 million to $370 million. It was previously guiding for $410.0 million to $430.0 million.

Ardelyx reaffirmed its long-term outlook for Ibsrela, but said it is evaluating the evolving market dynamics around the drug and how those dynamics could impact the timing of its $1 billion long-term sales target.

Ibsrela sales in the second quarter were below the company's expectations, primarily due to increased utilization-management processes from payors that Ardelyx isn't actively addressing.

Overall sales were just under Wall Street estimates at $120.9 million versus the $121 million expectation, according to FactSet. The loss per share of 7 cents was in line with analysts' projections.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657107612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657107612","market":"other","top_or_hot":-1,"title":"Ardelyx Shares Fall After IBS Drug Sales Hit Snags","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> shares were lower in pre-market trading after the company cut its outlook for its irritable bowel syndrome treatment. \n</p>\n<p>\n  The stock fell 20% to $3.90 before the opening bell Friday. Through the prior close, shares were already down 21% this year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said Thursday evening that it now expects full-year revenue for its IBS treatment Ibsrela to be $350 million to $370 million. It was previously guiding for $410.0 million to $430.0 million. \n</p>\n<p>\n  Ardelyx reaffirmed its long-term outlook for Ibsrela, but said it is evaluating the evolving market dynamics around the drug and how those dynamics could impact the timing of its $1 billion long-term sales target. \n</p>\n<p>\n  Ibsrela sales in the second quarter were below the company's expectations, primarily due to increased utilization-management processes from payors that Ardelyx isn't actively addressing. \n</p>\n<p>\n  Overall sales were just under Wall Street estimates at $120.9 million versus the $121 million expectation, according to FactSet. The loss per share of 7 cents was in line with analysts' projections. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx Shares Fall After IBS Drug Sales Hit Snags</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx Shares Fall After IBS Drug Sales Hit Snags\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-07 18:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> shares were lower in pre-market trading after the company cut its outlook for its irritable bowel syndrome treatment. \n</p>\n<p>\n  The stock fell 20% to $3.90 before the opening bell Friday. Through the prior close, shares were already down 21% this year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said Thursday evening that it now expects full-year revenue for its IBS treatment Ibsrela to be $350 million to $370 million. It was previously guiding for $410.0 million to $430.0 million. \n</p>\n<p>\n  Ardelyx reaffirmed its long-term outlook for Ibsrela, but said it is evaluating the evolving market dynamics around the drug and how those dynamics could impact the timing of its $1 billion long-term sales target. \n</p>\n<p>\n  Ibsrela sales in the second quarter were below the company's expectations, primarily due to increased utilization-management processes from payors that Ardelyx isn't actively addressing. \n</p>\n<p>\n  Overall sales were just under Wall Street estimates at $120.9 million versus the $121 million expectation, according to FactSet. The loss per share of 7 cents was in line with analysts' projections. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657107612","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657107612","pubTimestamp":1786098420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ardelyx shares were lower in pre-market trading after the company cut its outlook for its irritable bowel syndrome treatment.The stock fell 20% to $3.90 before the opening bell Friday. Through the prior close, shares were already down 21% this year.The commercial-stage biopharmaceutical company said Thursday evening that it now expects full-year revenue for its IBS treatment Ibsrela to be $350 million to $370 million. It was previously guiding for $410.0 million to $430.0 million.Ardelyx reaffirmed its long-term outlook for Ibsrela, but said it is evaluating the evolving market dynamics around the drug and how those dynamics could impact the timing of its $1 billion long-term sales target.Ibsrela sales in the second quarter were below the company's expectations, primarily due to increased utilization-management processes from payors that Ardelyx isn't actively addressing.Overall sales were just under Wall Street estimates at $120.9 million versus the $121 million expectation, according","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"IBS 药物销售遇阻后 Ardelyx 股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1.5},"content_text":"Ardelyx shares were lower in pre-market trading after the company cut its outlook for its irritable bowel syndrome treatment. \n\n\n  The stock fell 20% to $3.90 before the opening bell Friday. Through the prior close, shares were already down 21% this year. \n\n\n  The commercial-stage biopharmaceutical company said Thursday evening that it now expects full-year revenue for its IBS treatment Ibsrela to be $350 million to $370 million. It was previously guiding for $410.0 million to $430.0 million. \n\n\n  Ardelyx reaffirmed its long-term outlook for Ibsrela, but said it is evaluating the evolving market dynamics around the drug and how those dynamics could impact the timing of its $1 billion long-term sales target. \n\n\n  Ibsrela sales in the second quarter were below the company's expectations, primarily due to increased utilization-management processes from payors that Ardelyx isn't actively addressing. \n\n\n  Overall sales were just under Wall Street estimates at $120.9 million versus the $121 million expectation, according to FactSet. The loss per share of 7 cents was in line with analysts' projections.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657107612","isCrawlerRequest":true}